Best of Oncology West Conference 2025
Conference Venue: Sheraton Vancouver Wall Centre
Directions: Google Maps Link
Event Landscape
The Best of Oncology West 2025, chaired by Dr. Sharlene Gill and Dr. Daniel Heng, will take place in Vancouver at the Sheraton Vancouver Wall Centre. This in-person conference will highlight the most clinically relevant achievements for 2024 across several tumour sites. It will bring together the most influential oncologists from across Western Canada to discuss and explore the latest significant advancements in oncology.
Learning Objectives
- Examine pivotal oncology trials across various disease sites.
- Review current standards of care for key malignancies.
- Address ongoing controversies in the management of specific cancers.
Scientific Agenda
Click below to learn more about the scheduled presentations and incredible speaker lineup
Event Co-Chairs
Dr. Sharlene Gill
MD, MPH, MBA, FACP, FRCPC
Dr. Gill is a Professor of Medicine at the University of British Columbia and a medical oncologist specializing in gastrointestinal (GI) malignancies at BC Cancer – Vancouver. She received a Bachelor’s of Science in Pharmacy and an MD from the University of British Columbia in 1996 followed by residencies in Internal Medicine and Medical Oncology. Dr. Gill subsequently completed a fellowship in Gl Oncology at the Mayo Clinic (Rochester, MN) and a Master’s of Public Health from the Harvard School of Public Health. In 2017, she completed an MBA from the Kenan-Flagler School of Business at the University of North Carolina. She is actively engaged in education and research, with over 100 peer-reviewed publications and book chapters to her credit. Dr. Gill currently serves as the Chair of the Canadian Clinical Trials Group (CCTG) GI Disease Site Committee, and is President-Elect for the Canadian Association of Medical Oncologists.
Dr. Daniel Heng
MD, MPH, FRCPC
Dr. Daniel Heng is a Staff Medical Oncologist at the Tom Baker Cancer Center in Calgary, Alberta and a Clinical Professor of Medicine at the University of Calgary. He received his MD from the University of Calgary and completed his internal medicine and medical oncology residencies at the University of British Columbia in Vancouver, BC. He was trained at the BC Cancer Agency in Vancouver, Canada and then completed an Experimental Therapeutics fellowship at the Cleveland Clinic Taussig Cancer Institute. He received a Masters of Public Health from Harvard University. He is the Chair of the International mRCC Database Consortium (IMDC) which has created and validated the IMDC criteria (a.k.a. Heng Criteria) for prognostication in metastatic renal cell carcinoma patients. He is also the Chair of the Genitourinary Tumor Group in Calgary and the head of Medical Oncology at TBCC. He has a keen interest in outcomes, prognostic factors and clinical trials research in metastatic renal cell carcinoma and other genitourinary malignancies.
Registration for Healthcare professionals can be completed above. Industry representatives (both sponsor and non-sponsor) must contact Bernadette Gregoris at [email protected]. Industry registrations will not be accepted through the website.
Sponsorship
For sponsorship-related inquiries, please contact Bernadette Gregoris at [email protected].
Event Sponsors
Platinum sponsors
Silver sponsors
Bronze sponsors
All sales are final, refunds will not be accepted.
Please note mdBriefCase Group Inc. O/A Oncology Education cannot provide visa support for event attendees, including letters of invitation. Event attendees are solely responsible for obtaining any necessary documentation required for travel and participation in the event. No refunds shall be provided to individuals who are unable to attend.
